Bexarotene derivatives modify responses in acute myeloid leukemia
Hadwiger, G.; di Martino, O.; Ferris, M. A.; Vu, A.; Frederick, T. E.; Bowman, G. R.; Ruminski, P.; Wagner, C.; Welch, J. S.
Show abstract
The retinoids all-trans retinoic acid (ATRA) and bexarotene are active in acute myeloid leukemia (AML), but responses beyond acute promyelocytic leukemia (APL) have been more modest than APL responses. To determine whether chemical modification of bexarotene might augment retinoid responses in AML, we screened a series of 38 bexarotene derivatives for activity in a mouse MLL-AF9 leukemia cell line, which exhibits strong synergistic sensitivity to the combination of ATRA and bexarotene. We found that RXRA potency correlated with anti-leukemic activity and that only one compound (103-4) with dual RARA/RXRA activity was capable of ATRA-independent anti-leukemic activity. We evaluated bioisostere and cyclohexane modifications for potential resistance to P450 metabolism and found that bioisosteres reduced potency and that bezopyran, cyclopentane, and cyclohexene modifications only modestly reduced susceptibility to metabolism. Collectively, these studies provide a map of the structure-activity relationships of bexarotene with outcomes related to RXRA and RARA activity, corepressor binding, compound stability, and anti-leukemic potential.
Matching journals
The top 14 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1 92%
- Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX 92%
- PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4 91%
Similar papers in this journal
- A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease. 92%
- Identification of Celastrol as a novel HIV-1 Latency Reversal Agent by an Image-Based Screen 92%
- Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH) 92%
Similar papers in this journal
- Characterization of TR-107, a Novel Chemical Activator of the Human Mitochondrial Protease ClpP 93%
- Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase 89%
- Suspected Adverse Drug Reactions of the Type 2 Antidiabetic Drug Class Dipeptidyl-Peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? 88%
Similar papers in this journal
- Characterization of new highly selective pyrazolopyrimidine inhibitor of CDK7 94%
- Targeting AML Resistance with Two Novel Combinations Demonstrate Superior Efficacy in TP53, HLA-B, MUC4 and FLT3 mutations 93%
- Zebrafish Drug Screening Identifies Erlotinib as an Inhibitor of Wnt/β-Catenin Signaling and Self-Renewal in T-cell Acute Lymphoblastic Leukemia 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.